2018-11-12T13:07:30-06:00 2017-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2017-01-01 943384500 PATH DRUG SOLUTIONS PATH 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 OLIVIA D POLIUS CHIEF FINANCIAL OFFICER 2062853500 2018-11-12 1 3019519090 75.103.231.202 2018-11-12 14:07:25 ES P 4FA38BE9C690C82C721A5060F87FC7588CB81F81 92DED79A3FD2BE8CA1FF310A7D004DEBEF0EEB01 2017 2019-02-21 02:37:17Z OLIVIA D POLIUS 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 201146 0 X WWW.PATH.ORG X 2000 CA SEE PART III, LINE 1. 8 3 0 0 0 0 163077 146405 0 0 50401 53741 3000 1000 216478 201146 2597185 2009027 0 0 0 0 0 0 0 678532 539152 3275717 2548179 -3059239 -2347033 10229897 7105262 46385 708783 10183512 6396479 X THE MISSION OF PATH DRUG SOLUTIONS (PDS) IS TO DEVELOP AND ADVANCE SAFE AND EFFECTIVE MEDICINES FOR THE PREVENTION AND TREATMENT OF DISEASES DISPROPORTIONATELY AFFECTING WOMEN AND CHILDREN IN LOW-RESOURCE SETTINGS. WE WORK WITH A VARIETY OF PUBLIC- AND PRIVATE-SECTOR STAKEHOLDERS TO BUILD CROSS-SECTOR COLLABORATIONS, SECURE INTELLECTUAL PROPERTY, REVISIT PROMISING DRUGS OR DRUG CANDIDATES THAT HAVE BEEN SET ASIDE FOR NONMEDICAL REASONS (E.G., LACK OF EARNING POTENTIAL), AND HARNESS SCIENTIFIC AND MANUFACTURING CAPACITY IN HIGH- AND LOW- OR MIDDLE-INCOME COUNTRIES TO ENSURE THAT DRUGS ARE AVAILABLE, ACCESSIBLE, AFFORDABLE, AND ACCEPTABLE AND THAT SUPPLIES ARE SUSTAINABLE TO ALL THOSE WHO NEED THEM. 0 0 1951882 1563850 ESSENTIAL MEDICINES: IN 2017, PDS ADVANCED DRUG RESEARCH AND DEVELOPMENT TO COMBAT TOP GLOBAL HEALTH THREATS TO WOMEN AND CHILDREN THROUGH A NUMBER OF APPROACHES, INCLUDING WORKING THROUGH CROSS-SECTOR PARTNERSHIPS. (CONTINUED ON SCHEDULE O)TO COMBAT MALARIA WORLDWIDE, PDS CONTINUED WORK WITH RELEVANT FOUNDATION, UNIVERSITY, AND CORPORATE PARTNERS TO STREAMLINE INTELLECTUAL PROPERTY ISSUES AND POTENTIALLY ALLOW ADDITIONAL INTERESTED PARTIES TO MANUFACTURE SEMISYNTHETIC ARTEMISININ. ARTEMISININ IS A KEY PRECURSOR IN GOLD-STANDARD MALARIA TREATMENTS CALLED ARTEMISININ-BASED COMBINATION THERAPIES. ADDITIONAL PRODUCERS COULD CONTRIBUTE TO STABLE SUPPLIES OF THESE THERAPIES FOR USE IN GLOBAL MALARIA CONTROL AND ELIMINATION PROGRAMS. IN Q3 2017, PDS TRANSFERRED ITS ARTEMISININ GRANT TO PATH, WHERE THE WORK CONTINUES. IN ADDITION, PDS CONTINUED TO ADVANCE A LONG-ACTING INJECTABLE DRUG THAT MAY HELP PREVENT INFECTION WITH HIV WHEN USED BEFORE EXPOSURE (AN APPROACH CALLED PRE-EXPOSURE PROPHYLAXIS, OR PREP). PDS PROVIDED REGULATORY SPONSORSHIP OF A PHASE 2 TRIAL TO EVALUATE THE SAFETY AND ACCEPTABILITY OF INTRAMUSCULAR INJECTIONS. IN 2017, THE PHASE 2 CLINICAL STUDY WAS COMPLETED, WITH ALL PARTICIPANTS AT FOUR TRIAL SITES COMPLETING THE INJECTION AND FOLLOW-UP PHASES. PDS SUBSEQUENTLY SUBMITTED AN ABBREVIATED CLINICAL STUDY REPORT TO THE US FOOD AND DRUG ADMINISTRATION. PDS ALSO CONTINUED TO WORK WITH GLOBAL PARTNERS TO HELP DRIVE DOWN MORTALITY AND MORBIDITY DUE TO DIARRHEAL DISEASE, THE LEADING CAUSE OF DEATH AMONG CHILDREN UNDER FIVE IN LOW-RESOURCE SETTINGS. IN 2017, THIS WORK INCLUDED PREPARATION FOR A STAKEHOLDER CONVENING TO DISCUSS INNOVATIVE APPROACHES TO ENTERIC ENVIRONMENTAL DYSFUNCTION, A COMPLEX INTESTINAL SYNDROME THAT IMPAIRS YOUNG CHILDREN'S NUTRITION, REDUCES PROTECTION FROM ROUTINE VACCINES, INCREASES SUSCEPTIBILITY TO INFECTIONS, AND INTERFERES WITH COGNITIVE AND PHYSICAL DEVELOPMENT. 591948 445177 INTERNATIONAL DEVELOPMENT: IN 2017, PDS CONTINUED WORK TO REDUCE THE BURDEN OF VISCERAL LEISHMANIASIS (VL), ALSO KNOWN AS KALA-AZAR. VL IS A PARASITIC DISEASE COMMON IN AFRICA AND ASIA AND IS ALMOST ALWAYS FATAL IF UNTREATED. (CONTINUED ON SCHEDULE O)IN COLLABORATION WITH PARTNERS IN BANGLADESH AND NEPAL, PDS CONTINUED TO STRENGTHEN NATIONAL PHARMACOVIGILANCE PROGRAMS FOR VL ELIMINATION. THIS PHARMACOVIGILANCE AIMS TO IMPROVE PATIENT SAFETY AND CARE ASSOCIATED WITH THE USE OF VL DRUGS AND HAS BEEN ACCLAIMED BY THE GOVERNMENTS OF NEPAL AND BANGLADESH. PDS ALSO ADVANCED A POST-KALA-AZAR DERMAL LEISHMANIASIS (PKDL)/VL RELAPSE OBSERVATION STUDY IN BANGLADESH. PKDL SURVEILLANCE IS ESPECIALLY IMPORTANT BECAUSE PKDL SERVES AS A SIGNIFICANT SOURCE OF OVERALL VL TRANSMISSION. THE OBSERVATION STUDY WAS SUCCESSFULLY COMPLETED BY THE END OF 2017. TWO THERAPIES, INCLUDING A COMBINATION THERAPY INVOLVING PAROMOMYCIN INTRAMUSCULAR INJECTION (A PRODUCT DEVELOPED BY PATH), ARE ASSOCIATED WITH THE LEAST INCIDENCE OF PKDL AND VL RELAPSE.PDS ALSO ADVANCED A PHASE 3 MULTICENTER STUDY TO EVALUATE A POINT-OF-NEED SYSTEM FOR RAPID DETECTION OF LEISHMANIASIS IN ENDEMIC SETTINGS OF BANGLADESH, NEPAL, INDIA, AND SRI LANKA. TO BUILD CLINICAL RESEARCH CAPACITY IN INDIA, PDS WORKED TO FURTHER DEVELOP AND IMPLEMENT A CLINICAL RESEARCH TRAINING AND MENTORSHIP PROGRAM. THIS WORK WAS DONE IN COLLABORATION WITH THREE NATIONAL CLINICAL RESEARCH RESOURCE CENTERS SPECIALIZING IN PHARMACOVIGILANCE, RESEARCH ETHICS, AND DATA MANAGEMENT. 2543830 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 IN 0 0 0 0 0 0 0 0 X 8 3 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 CA WA X X OLIVIA POLIUS CHIEF FINANCIAL OFFICER 2062853500 2201 WESTLAKE AVENUE SUITE 200 SEATTLE WA 98121 STEPHEN B DAVIS BOARD CHAIR & PRESIDENT 1.00 39.00 X X 0 641522 65784 OLIVIA D POLIUS TREASURER & CFO 1.00 39.00 X X 0 311327 53104 DANIEL LASTER SECRETARY 1.00 39.00 X X 0 334058 41018 DAVID C KASLOW DIRECTOR 1.00 39.00 X 0 368007 67708 JORGE FLORES DIRECTOR 1.00 39.00 X 0 300097 42171 KEITH CHIRGWIN DIRECTOR 2.00 0.00 X 0 0 0 KEN DUNCAN DIRECTOR 2.00 0.00 X 0 0 0 DAN HARTMAN DIRECTOR 2.00 0.00 X 0 0 0 0 1955011 269785 0 0 1 0 0 146405 146405 53741 53741 REIMBURSEMENT 900099 1000 1000 1000 201146 0 0 54741 1884329 1884329 124698 124698 2877 2877 135010 135010 721 721 23864 23864 2474 2474 255410 255410 28606 28606 2064 1541 523 -14 1100 -1114 SUBCONTRACTS 69112 69112 EQUIPMENT R&M 12609 12609 MISC. TAXES 952 952 MEMBERSHIP DUES 250 250 5217 277 4940 2548179 2543830 4349 0 48385 105262 7000000 2048216 8126443 23 23869 23869 2064 0 4766 10229897 7105262 46385 708783 46385 708783 X 490746 558860 9692766 5837619 10183512 6396479 10229897 7105262 X -2347033 -1440000 X 0 1 X 1 0 X X 1 PATH 911157127 7 1 2548179 0 1 2548179 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 23869 23869 0 0 1 EUROPE 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 73006 EUROPE 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 749 SOUTH ASIA 0 4 PROGRAM SERVICES ESSENTIAL MEDICINE 2477 SOUTH ASIA 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 144462 SOUTH ASIA 0 0 GRANTMAKING 124698 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 244 0 4 0 0 0 4 345636 0 345636 SOUTH ASIA INTERNATIONAL DEVELOPMENT 42407 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 79086 CHECK/WIRE 2 0 1 0 0 0 0 0 PART I, LINE 2: PDS PERFORMS RISK-BASED MONITORING OF SUBRECIPIENTS. POLICIES AND PROCEDURES ARE IN PLACE TO GUIDE PROJECT TEAMS' FINANCIAL AND TECHNICAL MONITORING OF SUBRECIPIENTS. TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD STEWARDSHIP OF EVERY PROJECT, PDS USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, OR OTHER MEANS TO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND THAT IT ACHIEVES PERFORMANCE GOALS. 1 PATH 2201 WESTLAKE AVENUE SUITE 200 SEATTLE WA 98121 911157127 501(C)(3) 1884329 GENERAL SUPPORT 1 0 PART I, LINE 2: PDS PERFORMS RISK-BASED MONITORING OF SUBRECIPIENTS. POLICIES AND PROCEDURES ARE IN PLACE TO GUIDE PROJECT TEAMS' FINANCIAL AND TECHNICAL MONITORING OF SUBRECIPIENTS. TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD STEWARDSHIP OF EVERY PROJECT, PDS USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, OR OTHER MEANS TO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND THAT IT ACHIEVES PERFORMANCE GOALS. 0 0 0 0 0 0 0 0 0 STEPHEN B DAVIS BOARD CHAIR & PRESIDENT 0 486134 0 147638 0 7750 0 32200 0 33584 0 707306 0 0 OLIVIA D POLIUS TREASURER & CFO 0 309227 0 0 0 2100 0 32400 0 20704 0 364431 0 0 DANIEL LASTER SECRETARY 0 332258 0 0 0 1800 0 32400 0 8618 0 375076 0 0 DAVID C KASLOW DIRECTOR 0 358097 0 0 0 9910 0 32400 0 35308 0 435715 0 0 JORGE FLORES DIRECTOR 0 300097 0 0 0 0 0 32400 0 9771 0 342268 0 0 PART I, LINE 3 PDS RELIES ON A RELATED ORGANIZATION, PATH, TO DETERMINE COMPENSATION. PATH USES THE FOLLOWING TO ESTABLISH COMPENSATION OF THE EXECUTIVE DIRECTOR: - COMPENSATION COMMITTEE - INDEPENDENT COMPENSATION CONSULTANT - COMPENSATION SURVEY OR STUDY - APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM (GELMAN, ROSENBERG & FREEDMAN, CPAS), USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO PDS'S BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CHIEF FINANCIAL OFFICER SIGNED AND FILED THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C PDS HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PDS BOARD MEMBERS AND OFFICERS MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. PDS DOES NOT HAVE EMPLOYEES. PDS IS A SUPPORTING ORGANIZATION TO PATH WITHIN THE MEANING OF INTERNAL REVENUE CODE SECTION 509(A)(3) AND CONTRACTS WITH PATH FOR MANAGEMENT SERVICES. PATH HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PATH BOARD MEMBERS, OFFICERS, AND STAFF AT HIGHER THAN A DESIGNATED LEVEL MUST ANNUALLY COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM. ALL PDS AND PATH DISCLOSURE FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL AND, IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING. FORM 990, PART VI, SECTION C, LINE 19 PDS MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XI, LINE 9: FROM TIME TO TIME, UNSPENT AWARD FUNDS (OR UNUSED OBLIGATION) MAY BE RETURNED TO A FUNDER FOR A VARIETY OF REASONS INCLUDING, BUT NOT LIMITED TO, EARLY TERMINATION OF A PROJECT BY A FUNDER OR A REDUCTION IN FUNDS REQUIRED TO ACCOMPLISH A PROJECT'S SCOPE OF WORK. -1,440,000. PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 GLOBAL HEALTH WA 501(C)(3) LINE 7 N/A 0 PATH VACCINE SOLUTIONS 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 830431851 ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN WA 501(C)(3) LINE 12A, I PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ 501(C)(3) PATH 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0